Navigation Links
Echo Therapeutics Chairman and CEO to be Interviewed on Steve Crowley's American Scene Radio Program and Featured on Money Channel Inc.

FRANKLIN, Mass., Feb. 9 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., the Company's Chairman and CEO, will be interviewed on "Steve Crowley's American Scene National Radio" on Tuesday, February 9, 2010 at 9:34 AM ET and Thursday, February 11, 2010 at 10:24 AM ET.  Dr. Mooney also will be a regular on-air guest on American Scene twice weekly and will be interviewed by host Steve Crowley regarding relevant corporate events, news releases and updates.

Steve Crowley's American Scene National Radio, owned by the Money Channel Inc., airs for three hours daily Monday through Friday.  Money Channel also produces a national weekly television program, WallStreetCast, which airs on the FOX Business Network during certain times of the year.  American Scene was launched nationally in June 1990, and WallStreetCast has been produced since 2005.  Both programs feature personal finance advice, stock market-related news and advice, and they include regular CEO interviews of Micro-cap and Small-cap companies.  American Scene has over 3,000,000 listeners on the three-hour daily radio broadcasts and airs on hundreds of radio channels nation-wide through the IRN/USA Radio Network affiliates.

"We had the pleasure of being interviewed by Steve Crowley, a Wall Street legend, on his American Scene radio program last month and sharing our exciting story with his listeners," commented Dr. Mooney. "We are pleased to again join his popular program to provide listeners with an update on the progress of the product development completion on our Prelude SkinPrep System, the progress of our commercialization strategy and again discuss our market opportunities. The final Prelude device will be tested in the near-term in a study using LMX4 lidocaine cream which should form the basis for the 510-k filing with Ferndale Pharma Group for the enhanced delivery of lidocaine. We believe the addressable market for enhanced, fast acting topical lidocaine exceeds $1 billion. The timing of this interview is fortuitous as we believe we are at an inflection point with our completed product development, our FDA approval process and the beginning of the manufacturing scale-up for validation and product launch, setting the stage for a listing on a national exchange during 2010. We are working with Ferndale Pharma Group to generate cash flow to Echo from the topical anesthetic market in the US and UK during 2010 and we expect to begin generating revenue during 2010."

About Echo Therapeutics

Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

About Money Channel Inc.

The Money Channel Inc. is headquartered in Coconut Creek, Florida and has operated as a Media Company since 2004, and its CEO, Stephen Crowley is a former Price Waterhouse and Co. CPA-Manager, the former Money Editor of ABC's Good Morning America as well as the author of Money for Life, published by Simon & Schuster Inc.

Mr. Crowley and his team have produced more than 9,000 national Radio and Television programs since 1982 in markets ranging from New York to San Diego and from Seattle to Miami.  American Scene Radio is also co-branded with Investors Business Daily at and with "" founded by Jim Cramer.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.  Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of the Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to the Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to the Symphony tCGM System and the Prelude SkinPrep System.  These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

© 2002 - 2009 Echo Therapeutics, Inc. All rights reserved worldwide. 

SOURCE Echo Therapeutics, Inc.



SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
(Date:10/13/2015)... Calif. , Oct. 13, 2015  Asterias ... agreement with the UK-based Cell Therapy Catapult to ... AST-VAC2, Asterias, allogeneic dendritic cell immunotherapy. Under the ... scale manufacturing processes for AST-VAC2 to support advanced ... --> --> The ...
(Date:10/12/2015)... Apheresis is an invasive process that involves the ... components from whole blood. In this procedure, the blood of ... machine or a blood cell separator. The apheresis equipment spins ... components. A selected part of the blood is removed, and ... patient. It involves the use of devices and disposables along ...
(Date:10/12/2015)... 12, 2015  The Pharmacy Compounding Accreditation Board ... Pharmacy in Costa Mesa , ... the pharmacy,s commitment to meeting and/or exceeding national ... --> --> ... --> --> Harbor Compounding ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... According to an article published October 5th ... who successfully lose weight with a bariatric procedure are much less likely to develop ... notes that anywhere from 40 to 50 percent of all endometrial cancer cases are ...
(Date:10/13/2015)... , ... October 13, 2015 , ... Symposium Chairman, Dr. ... 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. The ... afterwards, draws plastic surgeons and cosmetic physicians from around the world. , Key topics ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... unique private messaging application, announced today a significant contract that will provide its ... Independence plans to build on the growing success of its Relay program, IBX ...
(Date:10/13/2015)... ... ... NavaFit Inc. today announced the launch of its NavaFit app for iPhone® ... fitness & sporting events, and stay motivated. Users can download the apps ... to get more serious about fitness and wellness, individuals are constantly looking for new ...
(Date:10/13/2015)... ... 2015 , ... Protein is essential to good health. You need it to ... how much protein does the average man need in order to stay healthy? ... 2015 issue of Harvard Men's Health Watch . Most Americans get about 15% ...
Breaking Medicine News(10 mins):